Clinical trials: Post-Essential Thrombocythemia MF (Post-ET-MF)
Primary Myelofibrosis, Post-Polycythemia Vera
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
- Trial name
- FREEDOM2 (NCT03952039)
- Testing
- FEDRATINIB, Best Available Therapy (BAT)
- Where
- 107 sites in Australia, Austria and 14 more
- Volunteers
- 202 people
- Sponsor
- Celgene
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- Simplify 2 (NCT02101268)
- Testing
- Momelotinib, Best Available Therapy (BAT)
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis (MF)
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential…
- Trial name
- NCT02087059
- Testing
- Ruxolitinib
- Where
- 29 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01423851
- Testing
- NS-018
- Where
- 9 sites in United States
- Volunteers
- 77 people
- Sponsor
- NS Pharma, Inc.
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
This was a prospective, two-arm, non-interventional study of JAKAVI® (Ruxolitinib) in patients with myelofibrosis
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- JAKoMo (NCT05044026)
- Testing
- Jakavi
- Where
- Germany
- Volunteers
- 1,012 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Polycythemia Vera
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocythemia
- Trial name
- NCT04629508
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 5 more
- Volunteers
- 4 people
- Sponsor
- Incyte Corporation
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF)
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera…
- Conditions
- Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
- Trial name
- NCT05835466
- Testing
- reparixin
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Leukemia, Myelofibrosis
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
The goal of this clinical research study is to learn if rigosertib can help to control MF in patients with anemia. The safety of this drug will also be studied. This is an investigational study.
- Conditions
- Leukemia, Myelofibrosis, Anemia, Splenomegaly
- Trial name
- NCT02730884
- Testing
- Rigosertib, Questionnaire
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Anemia, Primary Myelofibrosis
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells.
- Conditions
- Anemia, Primary Myelofibrosis, Secondary Myelofibrosis
- Trial name
- NCT01732445
- Testing
- ruxolitinib phosphate, danazol, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Primary Myelofibrosis, Polycythemia Vera
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by…
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01981850
- Testing
- RO7490677, Ruxolitinib
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 125 people
- Sponsor
- Hoffmann-La Roche
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
This phase II trial studies how well PAT-1251 works in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytosis myelofibrosis.
- Conditions
- Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Trial name
- NCT04054245
- Testing
- LOXL2 Inhibitor PAT-1251, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
LBH589 is an oral drug that targets the myelofibrosis cells in the bone marrow and induces cell death by allowing for the expression of certain suppressed genes that are important in regulating cell survival.
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
- Trial name
- NCT01298934
- Testing
- LBH589
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ronald Hoffman
Myeloproliferative Neoplasms
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
The purpose of this study is to test a new drug called AUY922. AUY922 is not FDA-approved. AUY922 is a new kind of drug that attacks a protein called HSP90.
- Trial name
- NCT01668173
- Testing
- AUY922
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
- Trial name
- NCT02515630
- Testing
- MMB
- Where
- 13 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis (PMF), Post-Polycythaemia Vera
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
- Trial name
- NCT00910728
- Testing
- AZD1480
- Where
- 3 sites in United States, France
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Myelofibrosis, Primary Myelofibrosis
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant ruxolitinib.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT03373877
- Testing
- PU-H71, Ruxolitinib
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- FREEDOM (NCT03755518)
- Testing
- FEDRATINIB
- Where
- 35 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Celgene
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
- Trial name
- NCT04878003
- Testing
- KRT-232, TL-895
- Where
- 29 sites in United States, Belarus and 7 more
- Volunteers
- 52 people
- Sponsor
- Kartos Therapeutics, Inc.